Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF-10101-01 in Relapsed or Refractory Acute Myeloid Leukemia
NCT03194685Phase 1Completed
- Sponsor
- Fujifilm Pharmaceuticals
- Start
- May 2017
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of FF-10101 in acute myeloid leukemia (AML) (8 arms), sponsored by Fujifilm Pharmaceuticals. Primary endpoint: Frequency of adverse events at 12 months. Started May 2017; status: completed.
02
Drugs
FF-10101
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03194685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03194685.